By Ben Glickman
Oragenics said it would transfer assets to Lantern Bioworks. Oragenics said it would receive $50,000 in cash, the right to acquire 1 million Lantern shares and 10% of the profits from the assets over the next decade. Shares rise 18%, to $3.51, after-hours.
Natuzzi said it would take cost-cutting measures and improve its working capital as it forecasts weaker demand in the furnishing business. The company said it would look to optimize its supply chain and reduce selling, general and administrative expenses. Shares rise 12%, to $7.93, after-hours.
Syndax Pharmaceuticals said it would release topline results from its Phase 1/2 study Oct. 2. The pharmaceutical company will discuss results from its trial of Revumenib to treat certain forms of leukemia. Shares rose 15%, to $16.73, after-hours.
Write to Ben Glickman at [email protected]
Read the full article here